Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Preventing anal cancer: the vaccine, and who screening is for

Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Anal cancer is one of the most preventable cancers there is, because its main cause is a virus a vaccine prevents and its precancer stage lasts years.

The difficulty is not knowing what to do. It is that the vaccine reaches people too late and screening is offered to too few.

Related pages: Anal cancer

The bottom line

What we know
  • The 9-valent HPV vaccine prevents infection with the types that cause most anal cancers.
  • The vaccine prevents infection; it does not treat an infection someone already has.
  • Screening with anal cytology and high-resolution anoscopy is offered to specific high-risk groups.
  • There is no routine anal screening for the general population.
What is still open
  • Whether screening should be extended to more groups, which is under active discussion.
  • How much benefit vaccination gives to adults who have already been exposed to some HPV types.

The story, step by step

  1. 1. The vaccine ()
  2. 2. Who is screened ()
  3. 3. How screening works ()
  4. 4. Treating precancer ()
  5. 5. The rest of prevention ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

What it does and does not do

Review of many studies

What happens

The 9-valent HPV vaccine covers nine HPV types, including 16 and 18, the main high-risk ones.

What the research shows

  • It prevents infection with types it covers. It works by preparing the immune system before exposure.
  • It does not treat an existing infection and does not clear a lesion someone already has.
  • Routine vaccination is recommended at ages 11 to 12 and can be started at 9. Catch-up vaccination is recommended through age 26.
  • For adults aged 27 to 45, vaccination is a shared decision with a clinician, since benefit depends on previous exposure.
  • It protects against anal, cervical, vulvar, vaginal, penile and oropharyngeal cancers caused by the covered types, so it is not only a cervical cancer vaccine.

Why it matters

The vaccine is given to children because it works best before any exposure, not because the cancers it prevents are childhood cancers.

What's still uncertain

  • Duration of protection appears long, but the vaccinated cohorts are still being followed.

Read more

Next: Who is screened

Part 2 of 5

The high-risk groups

Review of many studies

What happens

Anal cancer screening is targeted rather than universal, because the disease is uncommon in the general population.

What the research shows

  • People living with HIV, particularly men who have sex with men, are the group where screening is most clearly recommended.
  • Organ transplant recipients and others on long-term immunosuppression.
  • Women with a history of cervical, vulvar or vaginal high-grade precancer or cancer.
  • Men who have sex with men, including those without HIV, in some guidance.
  • Availability varies a great deal by country and by centre, and high-resolution anoscopy is not offered everywhere.

Why it matters

If you are in one of these groups, screening is something to ask about rather than wait to be offered, because it is not universally implemented.

What's still uncertain

  • Guidelines differ between countries and have been changing since the ANCHOR results.

Read more

Next: How screening works

Part 3 of 5

Cytology, then anoscopy

Review of many studies

What happens

The sequence resembles cervical screening, with a different instrument at the second step.

What the research shows

  • Anal cytology, sometimes called an anal Pap, samples cells from the anal canal with a swab. It is quick and does not require preparation.
  • An abnormal result leads to high-resolution anoscopy, HRA, in which a magnifying instrument is used to inspect the anal canal after applying acetic acid and iodine, which make abnormal areas visible.
  • Suspicious areas are biopsied during the procedure.
  • HRA requires specific training and is the limiting factor in how widely screening can be offered.
  • Some centres use HPV testing alongside cytology.

Why it matters

The bottleneck is not the test. It is the number of clinicians trained to do high-resolution anoscopy.

What's still uncertain

  • Anal cytology is less accurate than cervical cytology, and a normal result does not fully exclude high-grade disease.

Read more

Next: Treating precancer

Part 4 of 5

Before it becomes cancer

Review of many studies

What happens

When high-grade precancer is found, it can be removed.

What the research shows

  • Treatment options include ablation, often with electrocautery or infrared coagulation, and surgical excision of larger areas.
  • Topical treatments such as imiquimod or fluorouracil cream are used in some situations.
  • Treatment is usually done in clinic, and more than one session may be needed.
  • Recurrence is common, particularly with ongoing immunosuppression, which is why follow-up continues after treatment.
  • The ANCHOR trial showed this approach reduces progression to cancer by around 57 percent in people living with HIV.

Why it matters

Recurrence is expected rather than a failure. Screening in these groups is a long-term relationship, not a one-off test.

What's still uncertain

  • The best treatment method has not been established by head-to-head trials.

Read more

Next: The rest of prevention

Part 5 of 5

Things that are not a test

Review of many studies

What happens

Two further measures have evidence behind them and get less attention.

What the research shows

  • Stopping smoking reduces risk, and it is the main modifiable cofactor.
  • In people with HIV, effective antiretroviral treatment maintaining a good CD4 count supports the immune control of HPV, though it does not eliminate the raised risk.
  • Condoms reduce HPV transmission but do not prevent it entirely, since the virus spreads by skin contact beyond the area covered.
  • Anyone with anal symptoms that persist should be examined, whatever their risk group. Prevention and early diagnosis are not the same thing, and both matter.

Why it matters

Smoking cessation is worth stating plainly here because it is rarely mentioned alongside anal cancer, and it should be.

What's still uncertain

  • The size of the risk reduction from stopping smoking specifically for anal cancer is not precisely quantified.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.